References
- CDC. National Diabetes Statistic Report. Centers for Disease Control. 2014. [cited 2014 Jul 21 Available from: http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf
- IDF. IDF diabetes atlas sixth edition - 2014 update. Brussels: International Diabetes Federation; 2014.
- Professional practice committee for the standards of medical care in diabetes-2015. Diabetes Care. 2015;38(Supplement1):S88–S9.Epub 2014 Dec 30.
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American diabetes association and the European association for the study of diabetes. Diabetes Care. 2015;38(1):140–149. Epub 2014 Dec 30.
- Cramer JA, Benedict A, Muszbek N, et al. The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract. 2008;62(1):76–87. Epub 2007 Nov 07.
- Dailey G, Kim MS, Lian JF. Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients. J Int Med Res. 2002;30(1):71–79. Epub 2002 Mar 30.
- Boccuzzi SJ, Wogen J, Fox J, et al. Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care. 2001;24(8):1411–1415. Epub 2001 Jul 27.
- Iglay K, Qiu Y, Fan CS, et al. Risk factors associated with treatment discontinuation and down-titration in type 2 diabetes patients treated with sulfonylureas. Curr Med Res Opin. 2016;13:1–9. Epub 2016 May 14.
- Gregoire JP, Sirois C, Blanc G, et al. Persistence patterns with oral antidiabetes drug treatment in newly treated patients–a population-based study. Value Health. 2010;13(6):820–828. Epub 2010 Nov 09.
- Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Clin Ther. 2001;23(8):1311–1320. Epub 2001 Sep 18.
- Valensi P, De Pouvourville G, Benard N, et al. Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: the ODYSSEE observational study. Diabetes Metab. 2015;41(3):231–238. Epub 2015 May 16.
- Crawford AG, Cote C, Couto J, et al. Comparison of GE centricity electronic medical record database and national ambulatory medical care survey findings on the prevalence of major conditions in the United States. Popul Health Manag. 2010;13(3):139–150. Epub 2010 Jun 24.
- Kentucky Uo. Sulfonylurea Dosage Conversion Table. 2006 [cited 2013 May 16]. Available from: http://www.hosp.uky.edu/pharmacy/formulary/formtools/sulfonylurea.htm
- Cohen FJ, Neslusan CA, Conklin JE, et al. Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care. 2003;26(6):1847–1851. Epub 2003 May 27.
- Rathmann W, Kostev K, Gruenberger JB, et al. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis. Diabetes Obes Metab. 2013;15(1):55–61. Epub 2012 Aug 07.
- Davis KL, Tangirala M, Meyers JL, et al. Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy. Curr Med Res Opin. 2013;29(9):1083–1091. Epub 2013 Jun 06.
- Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American diabetes association and the endocrine society. Diabetes Care. 2013;36(5):1384–1395. Epub 2013 Apr 17.